|
1
|
Sawka AM, Straus S, Rodin G, Thorpe KE,
Ezzat S, Gafni A and Goldstein DP: Decision aid on radioactive
iodine treatment for early stage papillary thyroid cancer: Update
to study protocol with follow-up extension. Trials. 16:3022015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yuan Y, Fang M, Wu CY and Ling EA:
Scutellarin as a potential therapeutic agent for microglia-mediated
neuroinflammation in cerebral ischemia. Neuromolecular Med.
18:264–273. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Titov SE, Ivanov MK, Karpinskaya EV,
Tsivlikova EV, Shevchenko SP, Veryaskina YA, Akhmerova LG, Poloz
TL, Klimova OA, Gulyaeva LF, et al: miRNA profiling, detection of
BRAF V600E mutation and RET-PTC1 translocation in patients from
Novosibirsk oblast (Russia) with different types of thyroid tumors.
BMC Cancer. 16:2012016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yoruker EE, Terzioglu D, Teksoz S, Uslu
FE, Gezer U and Dalay N: MicroRNA expression profiles in papillary
thyroid carcinoma, benign thyroid nodules and healthy controls. J
Cancer. 7:803–809. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mutalib NS, Yusof AM, Mokhtar NM, Harun R,
Muhammad R and Jamal R: MicroRNAs and lymph node metastasis in
papillary thyroid cancers. Asian Pac J Cancer Prev. 17:25–35. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Feng H, Wang Y, Su J, Liang H, Zhang CY,
Chen X and Yao W: MicroRNA-148a suppresses the proliferation and
migration of pancreatic cancer cells by downregulating ErbB3.
Pancreas. 45:1263–1271. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang H, Wang Y, Xu T, Li C, Wu J, He Q,
Wang G, Ding C, Liu K, Tang H, et al: Increased expression of
microRNA-148a in osteosarcoma promotes cancer cell growth by
targeting PTEN. Oncol Lett. 12:3208–3214. 2016.PubMed/NCBI
|
|
8
|
Zhang J, Gill A, Atmore B, Johns A,
Delbridge L, Lai R and McMullen T: Upregulation of the signal
transducers and activators of transcription 3 (STAT3) pathway in
lymphatic metastases of papillary thyroid cancer. Int J Clin Exp
Pathol. 4:356–362. 2011.PubMed/NCBI
|
|
9
|
Kim YR, Byun HS, Won M, Park KA, Kim JM,
Choi BL, Lee H, Hong JH, Park J, Seok JH, et al: Modulatory role of
phospholipase D in the activation of signal transducer and
activator of transcription (STAT)-3 by thyroid oncogenic kinase
RET/PTC. BMC Cancer. 8:1442008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim DW, Chung HK, Park KC, Hwang JH, Jo
YS, Chung J, Kalvakolanu DV, Resta N and Shong M: Tumor suppressor
LKB1 inhibits activation of signal transducer and activator of
transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase
rearranged in transformation (RET)/papillary thyroid carcinoma
(PTC). Mol Endocrinol. 21:3039–3049. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Couto JP, Daly L, Almeida A, Knauf JA,
Fagin JA, Sobrinho-Simões M, Lima J, Máximo V, Soares P, Lyden D,
et al: STAT3 negatively regulates thyroid tumorigenesis. Proc Natl
Acad Sci USA. 109:pp. E2361–E2370. 2012; View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Trovato M, Grosso M, Vitarelli E, Ruggeri
RM, Alesci S, Trimarchi F, Barresi G and Benvenga S: Distinctive
expression of STAT3 in papillary thyroid carcinomas and a subset of
follicular adenomas. Histol Histopathol. 18:393–399.
2003.PubMed/NCBI
|
|
13
|
Liu Q, Guan JZ, Sun Y, Le Z, Zhang P, Yu D
and Liu Y: Insulin-like growth factor 1 receptor-mediated cell
survival in hypoxia depends on the promotion of autophagy via
suppression of the PI3K/Akt/mTOR signaling pathway. Mol Med Rep.
15:2136–2142. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mao Y, Xi L, Li Q, Cai Z, Lai Y, Zhang X
and Yu C: Regulation of cell apoptosis and proliferation in
pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
Oncol Rep. 36:49–56. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Petrulea MS, Plantinga TS, Smit JW,
Georgescu CE and Netea-Maier RT: PI3K/Akt/mTOR: A promising
therapeutic target for non-medullary thyroid carcinoma. Cancer
Treat Rev. 41:707–713. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gweon HM, Son EJ, Youk JH, Kim JA and Park
CS: Preoperative assessment of extrathyroidal extension of
papillary thyroid carcinoma: Comparison of 2- and 3-dimensional
sonography. J Ultrasound Med. 33:819–825. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lei S, Wang D, Ge J, Liu H, Zhao D, Li G
and Ding Z: Single-center study of familial papillary thyroid
cancer in China: Surgical considerations. World J Surg Oncol.
13:1152015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Proczko M, Stefaniak T, Sworczak K,
Kobiela J, Lachiński AJ, Stepaniak P and Sledziński Z: Completion
thyroidectomy of well-differentiated thyroid cancer - a
prospective, randomised study. Endokrynol Pol. 64:335–339. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shen CT, Qiu ZL, Song HJ, Wei WJ and Luo
QY: miRNA-106a directly targeting RARB associates with the
expression of Na(+)/I(−) symporter in thyroid cancer by regulating
MAPK signaling pathway. J Exp Clin Cancer Res. 35:1012016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Geraldo MV, Nakaya HI and Kimura ET:
Downregulation of 14q32-encoded miRNAs and tumor suppressor role
for miR-654-3p in papillary thyroid cancer. Oncotarget.
8:9597–9607. 2017.PubMed/NCBI
|
|
21
|
Yu B, Lv X, Su L, Li J, Yu Y, Gu Q, Yan M,
Zhu Z and Liu B: MiR-148a functions as a tumor suppressor by
targeting CCK-BR via inactivating STAT3 and Akt in human gastric
cancer. PLoS One. 11:e01589612016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li HP, Huang HY, Lai YR, Huang JX, Chang
KP, Hsueh C and Chang YS: Silencing of miRNA-148a by
hypermethylation activates the integrin-mediated signaling pathway
in nasopharyngeal carcinoma. Oncotarget. 5:7610–7624. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jin SM, Jang HW, Sohn SY, Kim NK, Joung
JY, Cho YY, Kim SW and Chung JH: Role of autophagy in the
resistance to tumour necrosis factor-related apoptosis-inducing
ligand-induced apoptosis in papillary and anaplastic thyroid cancer
cells. Endocrine. 45:256–262. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Saffar H, Sanii S, Emami B, Heshmat R,
Panah VH, Azimi S and Tavangar SM: Evaluation of MMP2 and Caspase-3
expression in 107 cases of papillary thyroid carcinoma and its
association with prognostic factors. Pathol Res Pract. 209:195–199.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dong W, Cui J, Tian X, He L, Wang Z, Zhang
P and Zhang H: Aberrant sonic hedgehog signaling pathway and STAT3
activation in papillary thyroid cancer. Int J Clin Exp Med.
7:1786–1793. 2014.PubMed/NCBI
|
|
26
|
Zhao P, Guan HT, Dai ZJ, Ma YG, Liu XX and
Wang XJ: Knockdown of SPOCK1 inhibits the proliferation and
invasion in colorectal cancer cells by suppressing the PI3K/Akt
pathway. Oncol Res. 24:437–445. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gonçalves AP, Videira A, Soares P and
Máximo V: Orthovanadate-induced cell death in RET/PTC1-harboring
cancer cells involves the activation of caspases and altered
signaling through PI3K/Akt/mTOR. Life Sci. 89:371–377. 2011.
View Article : Google Scholar : PubMed/NCBI
|
